1. Khan A, Bilezikian J. Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ. 2000; 163:184–7.
2. Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009; 94:351–65.
Article
3. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008; 93:3462–70.
Article
4. Mihai R, Simon D, Hellman P. Imaging for primary hyperparathyroidism: an evidence-based analysis. Langenbecks Arch Surg. 2009; 394:765–84.
Article
5. Kim YI, Jung YH, Hwang KT, Lee HY. Efficacy of 99mTc-sestamibi SPECT/CT for minimally invasive parathyroidectomy: comparative study with 99mTc-sestamibi scintigraphy, SPECT, US and CT. Ann Nucl Med. 2012; 26:804–10.
Article
6. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med. 1990; 31:1646–53.
7. Melloul M, Paz A, Koren R, Cytron S, Feinmesser R, Gal R. 99mTc-MIBI scintigraphy of parathyroid adenomas and its relation to tumour size and oxyphil cell abundance. Eur J Nucl Med. 2001; 28:209–13.
Article
8. Mshelia DS, Hatutale AN, Mokgoro NP, Nchabaleng ME, Buscombe JR, Sathekge MM. Correlation between serum calcium levels and dual-phase (99m)Tc-sestamibi parathyroid scintigraphy in primary hyperparathyroidism. Clin Physiol Funct Imaging. 2012; 32:19–24.
Article
9. Biertho LD, Kim C, Wu HS, Unger P, Inabnet WB. Relationship between sestamibi uptake, parathyroid hormone assay, and nuclear morphology in primary hyperparathyroidism. J Am Coll Surg. 2004; 199:229–33.
10. Carpentier A, Jeannotte S, Verreault J, Lefebvre B, Bisson G, Mongeau CJ, et al. Preoperative localization of parathyroid lesions in hyperparathyroidism: relationship between technetium-99m-MIBI uptake and oxyphil cell content. J Nucl Med. 1998; 39:1441–4.
11. Akin M, Atasever T, Kurukahvecioglu O, Dogan M, Gokaslan D, Poyraz A, et al. Preoperative detection of parathyroid adenomas with Tc-99m MIBI and Tc-99m pertechnetate scintigraphy: histopathological and biochemical correlation with Tc-99m MIBI uptake. Bratisl Lek Listy. 2009; 110:166–9.
12. Chen CC, Skarulis MC, Fraker DL, Alexander R, Marx SJ, Spiegel AM. Technetium-99m-sestamibi imaging before reoperation for primary hyperparathyroidism. J Nucl Med. 1995; 36:2186–91.
13. Leslie WD, Riese KT, Dupont JO, Peterdy AE. Parathyroid adenomas without sestamibi retention. Clin Nucl Med. 1995; 20:699–702.
Article
14. Hiromatsu Y, Ishibashi M, Nishida H, Okuda S, Miyake I. Technetium-99m tetrofosmin parathyroid imaging in patients with primary hyperparathyroidism. Intern Med. 2000; 39:101–6.
Article
15. Piga M, Bolasco P, Satta L, Altieri P, Loi G, Nicolosi A, et al. Double phase parathyroid technetium-99m-MIBI scintigraphy to identify functional autonomy in secondary hyperparathyroidism. J Nucl Med. 1996; 37:565–9.
16. Bhatnagar A, Vezza PR, Bryan JA, Atkins FB, Ziessman HA. Technetium-99m-sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability. J Nucl Med. 1998; 39:1617–20.
17. Williams JG, Wheeler MH, Aston JP, Brown RC, Woodhead JS. The relationship between adenoma weight and intact (1–84) parathyroid hormone level in primary hyperparathyroidism. Am J Surg. 1992; 163:301–4.
Article
18. Cantley LK, Ontjes DA, Cooper CW, Thomas CG, Leight GS, Wells SA Jr. Parathyroid hormone secretion from dispersed human hyperparathyroid cells: increased secretion in cells from hyperplastic glands versus adenomas. J Clin Endocrinol Metab. 1985; 60:1032–7.
Article
19. Randhawa PS, Mace AD, Nouraei SA, Stearns MP. Primary hyperparathyroidism: do perioperative biochemical variables correlate with parathyroid adenoma weight or volume? Clin Otolaryngol. 2007; 32:179–84.
Article
20. Kamani F, Najafi A, Mohammadi SS, Tavassoli S, Shojaei SP. Correlation of biochemical markers of primary hyperparathyroidism with single adenoma weight and volume. Indian J Surg. 2013; 75:102–5.
Article
21. Harris L, Yoo J, Driedger A, Fung K, Franklin J, Gray D, et al. Accuracy of technetium-99m SPECT-CT hybrid images in predicting the precise intraoperative anatomical location of parathyroid adenomas. Head Neck. 2008; 30:509–17.
Article
22. Oksuz MO, Dittmann H, Wicke C, Mussig K, Bares R, Pfannenberg C, et al. Accuracy of parathyroid imaging: a comparison of planar scintigraphy, SPECT, SPECT-CT, and C-11 methionine PET for the detection of parathyroid adenomas and glandular hyperplasia. Diagn Interv Radiol. 2011; 17:297–307.
23. Cheung K, Wang TS, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol. 2012; 19:577–83.
Article
24. Boi F, Lombardo C, Cocco MC, Piga M, Serra A, Lai ML, et al. Thyroid diseases cause mismatch between MIBI scan and neck ultrasound in the diagnosis of hyperfunctioning parathyroids: usefulness of FNA-PTH assay. Eur J Endocrinol. 2012; 168:49–58.
Article
25. Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management: a Canadian and international consensus. Osteoporos Int. 2017; 28:1–19.
Article
26. Sinha TK, Miller S, Feming J, Khairi R, Edmondson J, Johnston CC Jr, et al. Demonstration of a diurnal variation in serum parathyroid hormone in primary and secondary hyperparathyroidism. J Clin Endocrinol Metab. 1975; 41:1009–13.
Article
27. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005; 63:506–13.
Article
28. Nevo-Shor A, Kogan S, Joshua BZ, Bahat-Dinur A, Novack V, Fraenkel M. Seasonal changes in serum calcium, PTH and vitamin D levels in patients with primary hyperparathyroidism. Bone. 2016; 89:59–63.
Article